Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN

Trv Gp V LLC purchased a new position in shares of Septerna, Inc. (NASDAQ:SEPN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,215,591 shares of the company’s stock, valued at approximately $208,160,143,000. Septerna comprises about 41.8% of Trv Gp V LLC’s holdings, making the stock its 2nd largest holding. Trv Gp V LLC owned approximately 13.79% of Septerna as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. TRV GP VI LLC acquired a new position in Septerna in the second quarter valued at approximately $141,048,460,000. BlackRock Inc. acquired a new stake in Septerna during the second quarter worth $64,706,000. Goldman Sachs Group Inc. raised its position in Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after purchasing an additional 1,260,409 shares during the period. Janus Henderson Group PLC purchased a new stake in Septerna in the first quarter valued at $21,334,000. Finally, First Light Asset Management LLC acquired a new position in shares of Septerna in the 4th quarter valued at $17,308,000.

Insider Activity at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 25,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the sale, the chief operating officer directly owned 174,209 shares in the company, valued at $7,665,196. This represents a 12.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samira Shaikhly sold 11,798 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88. Following the sale, the insider directly owned 793 shares in the company, valued at $23,837.58. This represents a 93.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 72,828 shares of company stock worth $2,684,314 in the last three months. 5.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. HC Wainwright upped their target price on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Truist Financial increased their target price on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Raymond James Financial reiterated a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a research report on Tuesday, August 11th. Finally, Stifel Nicolaus set a $49.00 price target on shares of Septerna in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $51.33.

Septerna Stock Down 0.9%

NASDAQ:SEPN opened at $43.80 on Wednesday. The stock’s fifty day moving average is $36.37 and its two-hundred day moving average is $29.94. Septerna, Inc. has a 52 week low of $10.74 and a 52 week high of $51.10. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -81.11 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The business had revenue of $26.75 million during the quarter, compared to analysts’ expectations of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. On average, sell-side analysts expect that Septerna, Inc. will post -1.36 EPS for the current fiscal year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.